A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding
- 1 April 2017
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 49 (4) , 449-455
Abstract
No abstract availableKeywords
Funding Information
- University of Florida (UL1 TR000064)
This publication has 17 references indexed in Scilit:
- All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trialsInternational Journal of Antimicrobial Agents, 2013
- Imbalanced Mortality Evidence for Tigecycline: 2011, the Year of the Meta-analysisClinical Infectious Diseases, 2012
- Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority TrialsClinical Infectious Diseases, 2012
- Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysisThe Lancet Infectious Diseases, 2011
- Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2011
- Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2011
- Efficacy and safety of tigecycline: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2011
- Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious DiseaseAntimicrobial Agents and Chemotherapy, 2011
- Use of a clinically derived exposure–response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpointsDiagnostic Microbiology and Infectious Disease, 2009
- Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal InfectionsAntimicrobial Agents and Chemotherapy, 2008